You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):復創醫藥抗腫瘤新藥FCN-098膠囊獲批臨牀
格隆匯 06-18 17:19

格隆匯6月18日丨復星醫藥(600196.SH)宣佈,近日,公司控股子公司復創醫藥收到國家藥監局關於同意其研製的FCN-098膠囊(簡稱“該新藥”)用於晚期惡性腫瘤治療開展臨牀試驗的批准。復創醫藥擬於條件具備後於中國內地開展該新藥的I期臨牀試驗。

該新藥為集團自主研發的二代TRK小分子抑制劑,擬主要用於治療NTRK基因變異的晚期實體瘤。截至該本公吿日,全球範圍內尚無二代TRK小分子抑制劑產品獲批上市。截至2021年5月,集團現階段針對該新藥累計研發投入約為人民幣1716萬元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account